AstraZeneca shares rise

AstraZeneca shares rise as China probe update reassures
AstraZeneca on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising investor hopes that the impact of several probes in the country could be minor and leading its shares to rise about 5%.
AstraZeneca Could Pay $4.5 Million In China Scandal. Here's Why Shares Jumped.
AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.
Pharmalittle: We’re reading about a China probe of AstraZeneca, a ‘troubling’ Super Bowl ad, and more
A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super Bowl
AstraZeneca shareholders say they need clarity on China investigations
AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue overhanging shares: an investigation of a top executive by authorities in China, one of its key markets.
AstraZeneca gains as Q4 results clear China overhang
AstraZeneca (AZN) stock rises as its Q4 results which exceeded Street forecasts address concerns over its China investigation. Read more here.
AstraZeneca offers some reassurance on China challenges
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more
India Infoline9m
AstraZeneca India may sell North Bengaluru unit for ₹3,200 Crore
As per the reported property consultants, the company has issued a global mandate for selecting candidates for the said land ...
AstraZeneca's cancer drug tops list of new brands launched in 2024
Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...
The inside story of Britain’s failure to clinch £450mn AstraZeneca deal
How an agreement set up by the Tories and lauded by Labour fell victim to cost-cutting and UK curbs on drugs expenditure ...
Inside AstraZeneca’s abandoned UK vaccine plant deal as Labour and Tories face questions over £450m collapse
AstraZeneca’s planned vaccine hub for Liverpool is off the table - business editor Karl Matchett and Whitehall editor Kate ...
AstraZeneca Expects Revenue, Earnings Growth Despite Sales Drop in China
Strength in the pharmaceutical major’s oncology business offset weak China sales, but the company has warned of a potential ...
AstraZeneca reports better than expected profit on higher cancer drug sales
Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...
Peer demands answers on AstraZeneca deal collapse
Lord Storey says he fears Merseyside was "not a high priority" on the government's growth agenda.
Why AstraZeneca Topped the Market on Thursday
AstraZeneca unveiled both its fourth-quarter and full-year 2024 results before market open today, revealing that its total revenue was $14.89 billion. This represented a meaty 24% improvement over Q4 ...
AstraZeneca (AZN) Gets a Hold from Deutsche Bank
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on AstraZeneca (AZN – Research Report), with a ...
AstraZeneca reports strong results boosted by promising trials
AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of ...